There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-6


Brief Information

Target Synonym:B-cell stimulatory factor 2,Interferon beta-2,IL6,IFNB2,IL-6,Interleukin-6,Interleukin 6,Hybridoma Growth Factor,IFN-Beta-2,BSF-2,CDF,B-Cell Differentiation Factor,Interferon, Beta 2,Interleukin BSF-2,BSF2,HGF,HSF,CTL Differentiation Factor,Interleukin 6
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

IL6-H8218-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).

IL6-H4218-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

ActiveMax® Human IL-6, Tag Free (Cat. No. IL6-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2856-0.3636 ng/mL (Routinely tested).


Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Human IL-6 R alpha, Fc Tag (Cat. No. ILR-H5259) on Protein A Biosensor, can bind ActiveMax® Human IL-6, Tag Free(Cat. No. IL6-H4218) with an affinity constant of 35.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and  IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells,et.al. to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor  and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pomalidomide CDC-394; CC-4047; IMiD-1; IMID-4047 Approved Celgene Corp Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 Mainland China Multiple Myeloma Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2013-02-08 Central Nervous System Neoplasms; Anemia, Sickle Cell; Sarcoma, Kaposi; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Lymphoma, Non-Hodgkin; Primary Myelofibrosis; Lymphoma, Follicular; Prostatic Neoplasms; Sarcoma; Medulloblastoma; Lung Diseases, Interstitial; Multiple Myeloma; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Lymphoma, B-Cell; Bone Marrow Neoplasms; Solid tumours Details
Luminol sodium MP-1032 Approved Selvim, Metrio Psoriasis; Immune System Diseases null 1997-01-01 Coronavirus Disease 2019 (COVID-19); Immune System Diseases; Psoriasis Details
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Japan Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Idiopathic Pulmonary Fibrosis; Multiple Myeloma; HIV Wasting Syndrome; Erythema Nodosum; Leprosy, Lepromatous; Carcinoma, Hepatocellular Details
Siltuximab cCLB-8; CNTO-328 Approved Eusa Pharma, Janssen Global Services Llc Sylvant EU Castleman Disease Eusa Pharma (Netherlands) Bv 2014-04-23 Respiratory Distress Syndrome, Adult; Lymphoma, Non-Hodgkin; Lung Neoplasms; Castleman Disease; Colorectal Neoplasms; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Respiratory Tract Infections; Lung Diseases; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Pneumonia; Carcinoma, Renal Cell; Ovarian Neoplasms; Head and Neck Neoplasms Details
Lenalidomide IMID-5013; CDC-5013; CDC-501; ENMD-0997; CC-5013; IMiD-3 Approved Celgene Corp 瑞复美, Revlimid, Revimid (former Brand Name) EU Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular Celgene Europe Bv 2005-12-27 Radiculopathy; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Neoplasm Metastasis; Melanoma; Complex Regional Pain Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Waldenstrom Macroglobulinemia; Thrombocytopenia; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Prostatic Neoplasms; Lymphoma, Follicular; Reflex Sympathetic Dystrophy; Leukemia, Myeloid; Lymphoma, Mantle-Cell; Multiple Myeloma; Smoldering Multiple Myeloma; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Blood Protein Disorders; Leukemia-Lymphoma, Adult T-Cell; Paraproteinemias; Anemia; Lymphoma, B-Cell; HIV Infections; Solid tumours; Hematologic Diseases; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PXL-01 PXL-01 Phase 3 Clinical Promore Pharma Tissue Adhesions; Post-surgical adhesions Details
EBI-031 EBI-031 Phase 1 Clinical Sesen Bio Diabetic macular oedema; Uveitis Details
FB-704A FB-704; FB-704A Phase 1 Clinical Fountain Biopharma Arthritis, Rheumatoid Details
Anti-interleukin-6 receptor monoclonal antibody (Biocad) Phase 2 Clinical Biocad Autoimmune Diseases Details
Cis-urocanic acid Cis-UCA; UCA-001; UCA-002 Phase 2 Clinical Herantis Pharma Dry Eye Syndromes; Urinary Bladder Neoplasms; Xerophthalmia; Dermatitis, Atopic Details
Ziltivekimab COR-001 Phase 2 Clinical Astrazeneca Pharmaceutical Co Ltd Anemia; Renal Insufficiency, Chronic; Inflammation Details
MEDI-5117 WBP-216; MEDI-5117 Phase 1 Clinical Wuxi Apptec Co Ltd, Medimmune Arthritis, Rheumatoid Details
Gerilimzumab GB-224; RYI-008; ARGX-109 Phase 2 Clinical Argen-X Arthritis, Rheumatoid Details
PF-04236921 PF-4236921; PF-04236921 Phase 2 Clinical Pfizer Pharmaceuticals Ltd (China) Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Crohn Disease Details
Wogonin Phase 1 Clinical Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University Respiratory Tract Infections; Neoplasms Details
Clazakizumab ALD-518; ALD518-003; BMS-645429; BMS-945429 Phase 3 Clinical Alder Biopharmaceuticals Anemia; Graft vs Host Disease; Arthritis, Rheumatoid; Fatigue; Rejection of organ transplantation; Arthritis, Psoriatic; Inflammation; Cachexia; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Stomatitis Details
Tocilizumab biosimilar (Mycenax Biotech) Phase 1 Clinical Mycenax Biotech Inc Arthritis, Rheumatoid Details
DMT-210 DMT-200; DMT-210; DMT-220; SIG-990 Phase 2 Clinical Signum Dermalogix Rosacea; Dermatitis, Atopic Details
Olokizumab CDP-6038; Anti-IL6-UCB Phase 3 Clinical Ucb Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Arthritis; Crohn Disease Details
CD24-Fc MK-7110; MK7110; HAS-CD24; CD24-Fc-IgG; CD24-Fc Phase 3 Clinical Oncoimmune HIV Infections; Hematopoietic stem cell transplantation (HSCT); Leukemia; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Dyslipidemias; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Melanoma Details
Monoclonal Antibody (Mab) sB24M Phase 1 Clinical Pyoderma Gangrenosum Details
HL-2351 GX-P4; HL-2351; rhIL-1Ra-hyFc Phase 1 Clinical Genexine Inc Arthritis, Rheumatoid; Cryopyrin-Associated Periodic Syndromes Details

This web search service is supported by Google Inc.